Characterization of humoral responses of ovarian cancer patients: Antibody subclasses and antigenic components

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 213-221

  Taylor, Douglas D ^a   Atay, Safinur ^a   Metzinger, Daniel S ^a   Gercel Taylor, Cicek ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Autoantibodies; Early detection; IgG subclasses; Ovarian cancer

Indexed keywords

ANTIBODY; CELL NUCLEUS ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; MEMBRANE ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN RECOGNITION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CASE REPORT; ELECTROPHORESIS; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOREACTIVITY; MASS SPECTROMETRY; OVARY CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITOPES; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 73949116302     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.005     Document Type: Article

References (40)

1. Memarzadeh S., and Berek J.S. Advances in the management of epithelial ovarian cancer. J. Reprod. Med. 46 (2001) 621-629
2. Hoskins W.J. Prospective on ovarian cancer: why prevent?. J. Cell. Biochem. 23 Suppl (1995) 189-199
3. Clark-Pearson D.L. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med. 361 (2009) 170-177
4. Nossov V., Amneus M., Su F., Lang J., Janco J.M.T., Reddy S.T., et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than CA-125. Am. J. Obstet. Gynecol. 199 (2008) 215-223
5. Bast R.C., Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 15 Suppl. 3 (2005) 274-281
6. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell. Proteomics. 3 (2004) 355-366
7. Zhang H., Kong B., Qu X., Jia L., Deng B., and Yang Q. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol. Oncol. 102 (2006) 61-66
8. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., and Steinberg S.M. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
9. Petricoin E.F., Belluco C., Arauio R.P., and Liotta L.A. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6 (2006) 961-967
10. Angelopoulou K., Yu H., Bharaj B., Giai M., and Diamandis E.P. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin. Biochem. 33 (2000) 53-62
11. Harpio R., and Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem. 37 (2004) 512-518
12. Gregorakis A.K., Stefanakis S., Malovrouvas D., Petraki K., Gourgiotis D., and Scorilas A. Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy. Prostate 68 (2008) 759-765
13. Yoshimasu T., Maebeya S., Suzuma T., Bessho T., Tanino H., Arimoto J., et al. Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int. J. Biol. Markers 14 (1999) 99-105
14. Thorpe J.D., Duan X., and Forrest R. Effects of blood collection conditions on ovarian cancer serum markers. PLoS ONE 2 (2007) e1281
15. Lutz A.M., Willmann J.K., Cochran F.V., Ray P., and Gambhir S.S. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS. Med. 5 (2008) 1287-1297
16. Draghici S., Chatterjee M., and Tainsky M.A. Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert. Rev. Mol. Diagn. 5 (2005) 735-743
17. Gagnon A., Kim J.H., Schorge J.O., Ye B., Liu B., Hasselblatt K., et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin. Cancer Res. 14 (2008) 764-771
18. Gercel-Taylor C., Bazzett L.B., and Taylor D.D. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol. Oncol. 81 (2001) 71-76
19. Taylor D.D., and Gercel-Taylor C. Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance?. Oncol. Rep. 5 6 (1998) 1519-1524 (review)
20. Nesterova M., Johnson N., Cheadle C., and Cho-Chung Y.S. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim. Biophys. Acta. 1762 (2006) 398-403
21. Tang R., Ko M.C., Wang J.Y., Changchien C.R., Chen H.H., Chen J.S., et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer 94 (2001) 859-863
22. Taylor D.D., and Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110 (2008) 13-21
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
24. Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtesek B., et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer 55 (1993) 678-684
25. Taylor D.D., Gercel-Taylor C., and Parker L.P. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol. Oncol. 115 (2009) 112-120
26. 2 perspective. J. Natl. Cancer Inst. 88 7 (1996) 461-462
27. Taylor D.D., Homesley H.D., and Doellgast G.J. Identification of antigenic components recognized by "membrane bound" antibodies from ovarian cancer patients. Am. J. Reprod. Immunol. 6 (1984) 179-184
28. Marx D., Frey M., Zentgraf H., Adelssen G., Schauer A., Kuhn W., et al. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer. Cancer Detect. Prevent. 25 (2001) 117-122
29. Pfreundschuh M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer. Chemother. Pharmacol. 46 Suppl (2000) S3-S7
30. Taylor D.D., and Doellgast G.J. Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Analytical. Biochem. 98 (1979) 53-59
31. Ravetch J.V., and Bolland S. IgG Fc receptors. Annual. Rev. Immunol. 19 (2001) 275-290
32. Bandyopadhyay S., Bhattacharyya A., Mallick A., Sen A.K., Tripathi G., Das T., et al. Over-expressed IgG2 antibodies against O-acetylated sialoglycoconjugates incapable of proper effector functioning in childhood acute lymphoblastic leukemia. Intl. Immunol. 17 (2005) 177-191
33. Soiffer R.J., Murray C., Ritz J., Phillips N., Jacobsohn D., Chartier S., et al. Recombinant interleukin-2 infusion and decreased IgG2 subclass concentrations. Blood 85 (1995) 925-928
34. Taylor D.D., Homesley H.D., and Doellgast G.J. Binding of specific peroxidase-labeled antibody to placental-type alkaline phosphatase on tumor-derived membrane fragments. Cancer Res. 40 (1980) 4064-4069
35. Chatterjee M., Wojciechowski J., and Tainsky M.A. Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput. Methods Mol. Biol. 520 (2009) 21-38
36. Chatterjee M., Mohapatra S., Ionan A., Bawa G., Ali-Fehmi R., Wang X., et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 66 (2006) 1181-1190
37. Nishikawa H., Tanida K., Ikeda H., Sakakura M., Miyahara Y., Aota T., et al. Role of SEREX defined immunogenic wild-type cellular molecules in the development of tumor specific immunity. Proc. Natl. Acad. Sci. USA. 98 (2001) 14571-14576
38. Singh A.P., Senapati S., Ponnusamy M.P., Jain M., Lele S.M., Davis J.S., et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 9 (2008) 1076-1085
39. Kim K., Visintin I., Alvero A.B., and Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin. Lab. Med. 29 (2009) 47-55
40. Herzog T.J. Recurrent ovarian cancer: how important is it to treat to disease progression. Clin. Cancer Res. 10 (2004) 7439-7449